SCHEMBL23948444

SCHEMBL23948444

COc1ncc(-c2cnn(-c3cnn4ccc(=O)[nH]c34)c2)cn1

nearest known ligand 0.31

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.31
BMPR1B O00238 1/20 0.31
BMPR1A P36894 1/20 0.31
ACVRL1 P37023 1/20 0.31
TGFBR2 P37173 1/20 0.31
ACVR1 Q04771 1/20 0.31
BMPR2 Q13873 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
ABL1 P00519 1/20 0.31
BCR P11274 1/20 0.31
HCAR1 Q9BXC0 2/20 0.31
PLAT P00750 1/20 0.31
MAPKAPK2 P49137 1/20 0.30
PLK4 O00444 1/20 0.30
AURKA O14965 1/20 0.30
DYRK3 O43781 1/20 0.30
MAP4K4 O95819 1/20 0.30
NTRK1 P04629 1/20 0.30
INSR P06213 1/20 0.30
CDK1 P06493 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26306189 0.87 PIK3CD (0.31) HCAR1
SCHEMBL23947947 0.87 PLAT (0.41) PLATMKNK2
SCHEMBL26306173 0.83 ADORA3 (0.33)
SCHEMBL23948325 0.82 FLT3 (0.34) KDRBMPR1BBMPR1AACVRL1TGFBR2
SCHEMBL23948320 0.82 EGLN1 (0.32)
SCHEMBL23948323 0.82 MAPK1 (0.38) ACVR1AURKAAURKBMKNK2
SCHEMBL23948294 0.81 CYP11B1 (0.38) ABL1BCRPLATMAPKAPK2MKNK2
SCHEMBL23947980 0.81 HCAR1 (0.35) KDRHCAR1PLAT
SCHEMBL26309079 0.81 HCAR1 (0.36) HCAR1PLAT
SCHEMBL26308858 0.81 JAK2 (0.34) KDRGSK3ADYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
WO-2021211882-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS LTK, FRK, LCK KDR 97/4885BMPR1B 1940/4885BMPR1A 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.